Rigel Pharma (RIGL) – Major News
-
Rigel Pharma (RIGL) Tops Q4 EPS by 2c, Tops on Revenue
-
Rigel Pharma (RIGL) Tops Q3 EPS by 4c
-
Rigel Pharma (RIGL) Tops Q2 EPS by 12c
-
Rigel Pharma (RIGL) Tops Q1 EPS by 2c
-
Rigel Pharma (RIGL) Tops Q4 EPS by 10c
-
Rigel Pharma (RIGL) Tops Q2 EPS by 4c
-
Rigel Pharma (RIGL) Misses Q1 EPS by 2c
-
Rigel Pharma (RIGL) Reports In-Line Q4 EPS
-
Rigel Pharma (RIGL) Misses Q3 EPS by 2c
-
Rigel Pharma (RIGL) Reports In-Line Q4 EPS, Revenues Beat
-
Rigel Pharma (RIGL) Reports In-Line Q1 EPS, Revenues Miss
-
Rigel Pharma (RIGL) Misses Q4 EPS by 2c, Revenues Miss
-
Rigel Pharma (RIGL) Tops Q3 EPS by 4c
-
Rigel Pharma (RIGL) Tops Q2 EPS by 2c, Revenues Beat
-
Rigel Pharma (RIGL) Tops Q1 EPS by 2c
-
Rigel Pharma (RIGL) Misses Q4 EPS by 1c, Revenues Beat
-
Rigel Pharma (RIGL) Tops Q3 EPS by 1c
-
Rigel Pharma (RIGL) Reports In-Line Q2 EPS
-
Rigel Pharma (RIGL) Tops Q1 EPS by 1c
-
Rigel Pharma (RIGL) Says Phase 2 Study of Fostamatinib in IgA Did Not Achieve Statistical Significance for its Primary Endpoint
-
Rigel Pharma (RIGL) Misses Q4 EPS by 5c
-
Rigel Pharma (RIGL) Tops Q3 EPS by 1c
-
Rigel Pharma (RIGL) Misses Q2 EPS by 1c
-
Rigel Pharma (RIGL) Misses Q1 EPS by 1c
-
Rigel Pharma (RIGL) Tops Q4 EPS by 1c
-
Rigel Pharma (RIGL) Misses Q3 EPS by 1c
-
Rigel Pharma (RIGL) Announced Second FIT Phase 3 of Fostamatinib Did Not Meet Primary Endpoint
-
Rigel Pharma (RIGL) Tops Q2 EPS by 5c
-
Rigel Pharma (RIGL) Reports In-Line Q1 Loss
-
Rigel Pharma (RIGL) Reports In-Line Q4 EPS
-
Rigel Pharma (RIGL) Tops Q3 EPS by 9c
-
Rigel Pharma (RIGL) Tops Q2 EPS by 6c
-
Rigel Pharma (RIGL) Misses Q4 EPS by 3c
-
Rigel Pharma (RIGL) Posts Smaller than Expected Q3 Loss
-
Rigel Pharmaceuticals, Inc. (RIGL) Misses Q2 EPS by 4c
-
Rigel Pharmaceuticals, Inc. (RIGL) Reports In-Line Q1 Loss
-
Rigel Pharma (RIGL) Posts Q4 Loss of 19c/Share
-
Rigel Pharmaceuticals, Inc. (RIGL) Posts Q3 Loss of 27c/Share
-
Rigel Pharma (RIGL) Reports R333 Missed Primary Endpoint, Will Cancel Development
-
Rigel Pharma (RIGL) Reports R343 Missed Primary Endpoint in Phase 2
-
Rigel Pharmaceuticals, Inc. (RIGL) Posts Q2 Loss of 26c/Share
-
Rigel Pharmaceuticals, Inc. (RIGL) Tops Q1 Loss Views
-
Rigel Pharmaceuticals, Inc. (RIGL) Narrows Q4 Loss to 30c/Share
-
Rigel Pharmaceuticals, Inc. (RIGL) Posts Q3 Loss of 36c/Share
-
Rigel Pharmaceuticals, Inc. (RIGL) Reports In-Line Q2 EPS
-
Rigel Pharmaceuticals (RIGL) Posts Wider than Expected Q4 Loss of 36c/Share
-
Rigel Pharmaceuticals, Inc. (RIGL) Reports Q3 Loss of $0.25
-
Rigel Pharmaceuticals (RIGL) Posts Q2 Loss of 37c/Sh., Tops Views
-
Rigel Pharma (RIGL) Misses Q1 EPS by 4c
-
Rigel Pharma (RIGL) Posts Narrower than Expected Q4 Loss
Back to RIGL Stock Lookup